Stabilized Sulforaphane


PharmAgra and Lalilab to receive patent on stabilized sulforaphane.

PharmAgra Labs Inc (Brevard, NC) and Lalilab Inc. (Durham, NC) have received a Notice of Allowance for their U.S. patent application for Stabilized Sulforaphane.

Sulforaphane is a compound available from cruciferous vegetables in the form of glucoraphanin.

“The cancer preventative benefit of cruciferous vegetables (such as broccoli) is widely believed to be due to a molecule called glucoraphanin, which upon consumption converts to the bioactive molecule sulforaphane,” said PharmAgra in a recent news announcement. “While sulforaphane has been well studied with regard to its mechanism of action in chemoprevention, it has been an unrealistic drug candidate due to poor stability and a lack of intellectual property. The granting of this patent is a major milestone in the commercialization of this most promising molecule.”

Evgen Limiited (Sheffield, UK) has obtained exclusive licensing rights for stabilized sulforaphane (Sulforadex) in medical applications. The ingredient is intended to be developed as a safe, low-cost medicine for patients with prostate cancer.

Related Videos
Nils Hoem and Nutritional Outlook editor Sebastian Krawiec
Related Content
© 2024 MJH Life Sciences

All rights reserved.